The possible impact of AI on life sciences in IP strategies

A stream of recent licensing deals between big pharma companies and AI-driven drug development innovators reflects an evolution that has been picking up pace in recent years. Pharmaceutical companies are integrating, more and more, artificial intelligence and other data-based technologies into their business models. This trend suggests pharma innovators are leaning increasingly heavily on AI technology owners. The increase in cash flow into the healthcare AI sector could lead to several IP strategy implications for life sciences organisations, pointed out in IAM Media’s article. More…